

**Table S1.** Correlation of ILEI and uPAR IHC status with established clinical and histopathological parameters of human breast cancer.

| Patient parameters       | uPAR | granular   |             | cytoplasmatic |             | p-value |
|--------------------------|------|------------|-------------|---------------|-------------|---------|
|                          |      | low (n=28) | high (n=16) | low (n=6)     | high (n=38) |         |
| <b>Age of onset</b>      |      |            |             |               |             |         |
| <50 (n=33)               |      | 9 (32.1)   | 5 (31.3)    | 3 (50.0)      | 16 (42.1)   | 0.7350  |
| ≥50 (n=55)               |      | 19 (67.9)  | 11 (68.8)   | 3 (50.0)      | 22 (57.9)   |         |
| <b>Tumor type</b>        |      |            |             |               |             |         |
| ductal (n=65)            |      | 19 (67.9)  | 13 (81.3)   | 5 (83.3)      | 28 (77.8)   | 0.7592  |
| lobular (n=21)           |      | 9 (32.1)   | 3 (18.8)    | 1 (16.7)      | 8 (22.2)    |         |
| other, na (n=2)          |      | 0          | 0           | 0             | 2           |         |
| <b>Tumor size</b>        |      |            |             |               |             |         |
| pT1 (n=25)               |      | 9 (32.1)   | 5 (31.3)    | 2 (33.3)      | 9 (25.7)    | 0.9052  |
| pT2-4 (n=60)             |      | 19 (67.9)  | 11 (68.8)   | 4 (67.7)      | 26 (74.3)   |         |
| na (n=3)                 |      | 0          | 0           | 0             | 3           |         |
| <b>Tumor grade</b>       |      |            |             |               |             |         |
| pG1-2 (n=45)             |      | 17 (60.7)  | 7 (43.8)    | 2 (33.3)      | 19 (54.3)   | 0.5750  |
| pG3 (n=40)               |      | 11 (39.3)  | 9 (56.3)    | 4 (66.7)      | 16 (45.7)   |         |
| na (n=3)                 |      | 0          | 0           | 0             | 3           |         |
| <b>Tumor stage</b>       |      |            |             |               |             |         |
| 1 (n=17)                 |      | 7 (26.9)   | 3 (21.4)    | 1 (16.7)      | 6 (18.8)    | 0.9066  |
| 2-4 (n=61)               |      | 19 (73.1)  | 11 (78.6)   | 5 (83.3)      | 26 (81.3)   |         |
| na (n=10)                |      | 2          | 2           | 0             | 6           |         |
| <b>Lymph node status</b> |      |            |             |               |             |         |
| pN0 (n=29)               |      | 14 (51.9)  | 5 (33.3)    | 1 (16.7)      | 9 (27.3)    | 0.1883  |
| pN+ (n=52)               |      | 13 (48.1)  | 10 (66.7)   | 5 (83.3)      | 24 (72.7)   |         |
| na (n=7)                 |      | 1          | 1           | 0             | 5           |         |
| <b>ER status</b>         |      |            |             |               |             |         |
| neg (n=50)               |      | 16 (57.1)  | 8 (53.3)    | 4 (66.7)      | 22 (61.1)   | 0.9335  |
| pos (n=35)               |      | 12 (42.9)  | 7 (46.7)    | 2 (33.3)      | 14 (38.9)   |         |
| na (n=3)                 |      | 0          | 1           | 0             | 2           |         |
| <b>PR status</b>         |      |            |             |               |             |         |
| neg (n=54)               |      | 17 (63.0)  | 9 (60.0)    | 4 (80.0)      | 24 (68.6)   | 0.8504  |
| pos (n=28)               |      | 10 (37.0)  | 6 (40.0)    | 1 (20.0)      | 11 (31.4)   |         |
| na (n=6)                 |      | 1          | 1           | 1             | 3           |         |
| <b>HER2 status</b>       |      |            |             |               |             |         |
| neg (n=68)               |      | 25 (89.3)  | 15 (93.8)   | 3 (50.0)      | 25 (69.4)   | 0.0271  |
| pos (n=18)               |      | 3 (10.7)   | 1 (6.3)     | 3 (50.0)      | 11 (30.6)   |         |
| na (n=2)                 |      | 0          | 0           | 0             | 2           |         |
| <b>p53 status</b>        |      |            |             |               |             |         |
| neg (n=56)               |      | 16 (57.1)  | 13 (81.3)   | 5 (83.3)      | 22 (57.9)   | 0.2608  |
| pos (n=32)               |      | 12 (42.9)  | 3 (18.8)    | 1 (16.7)      | 16 (42.1)   |         |
| <b>Ki67 pos cells</b>    |      |            |             |               |             |         |
| <10% (n=55)              |      | 16 (59.3)  | 11 (78.6)   | 4 (66.7)      | 24 (64.9)   | 0.6978  |
| ≥10% (n=29)              |      | 11 (40.7)  | 3 (21.4)    | 2 (33.3)      | 13 (35.1)   |         |
| na (n=4)                 |      | 1          | 2           | 0             | 1           |         |

The number of patients (n) and their relative frequencies (in %; figures in parentheses) in the indicated clinical and histopathological categories are shown. p-value, Fisher's exact test p-values; pN0, no lymph node metastases; pN+ patient has lymph node metastases; na, status not available. Note that na subjects were not included in the calculations of percentages and p-values.